Table II.
Modulation in hepatotoxicity and kidney toxicity parameters after treatment with different xanthones, mangosteen and cisplatin at IC50 dosage
| Groups (Dose in µM) | ALP (IU/l) | AST (IU/l) | ALT (IU/l) | Urea (mg/dl) | Creatinine (mg/dl) |
|---|---|---|---|---|---|
| Normal | 45.8±0.8 | 225±5 | 71±9 | 49±5 | 0.5±0.05 |
| EAC | 192.8±4.8 | 889±7 | 331±8 | 129±8 | 1.4±0.1 |
| Cisplatin (20) | 158±8 | 720±6 | 231±4 | 98±9 | 1.6±0.2 |
| Mangosteen (15) | 120±3 | 345±6 | 95±6 | 66±2 | 0.9±0.08 |
| XA-treated (48) | 103±3 | 350±1 | 91±3 | 71±8 | 1.7±0.09 |
| XB-treated (48) | 160±5 | 335±8 | 93±4 | 67±8 | 1.1±0.09 |
| XC-treated (32.35) | 106±2 | 355±9 | 85±5 | 79±8 | 1.2±0.09 |
| XD-treated (8.1) | 57.2±2 | 205±5 | 79±2 | 41±8 | 0.7±0.09 |
Values represent mean±SD of six samples in each group. Comparative study of biochemical parameters (ALP, AST, ALT, urea and creatinine) of normal, EAC control, cisplatin-, mangosteen-, XA-, XB-, XC- and XD-treated groups of mice. Significant difference was observed in the XD-treated group’s biochemical parameters compared with the EAC control group considering P<0.001. ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase